Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 12.10B | 11.86B | 11.15B | 10.10B | 8.89B | 7.15B |
Gross Profit | 3.54B | 3.47B | 3.16B | 2.83B | 2.37B | 1.82B |
EBITDA | 272.63M | 268.21M | 161.50M | 138.56M | -17.72M | -54.80M |
Net Income | 388.24M | 392.74M | 39.58M | 49.90M | -75.46M | -94.51M |
Balance Sheet | ||||||
Total Assets | 3.06B | 3.01B | 3.19B | 2.52B | 2.09B | 1.74B |
Cash, Cash Equivalents and Short-Term Investments | 616.40M | 596.66M | 1.13B | 677.38M | 603.08M | 563.35M |
Total Debt | 500.20M | 502.40M | 527.79M | 471.76M | 410.17M | 328.23M |
Total Liabilities | 2.68B | 2.75B | 2.68B | 2.30B | 2.07B | 1.74B |
Stockholders Equity | 375.60M | 261.46M | 510.24M | 213.96M | 14.74M | -2.00M |
Cash Flow | ||||||
Free Cash Flow | 448.56M | 452.49M | 342.93M | 119.28M | 8.55M | 2.01M |
Operating Cash Flow | 600.79M | 596.33M | 486.21M | 349.57M | 191.74M | 132.75M |
Investing Cash Flow | -152.33M | 394.57M | -287.36M | -615.48M | -193.27M | -123.69M |
Financing Cash Flow | -966.67M | -996.74M | 71.60M | -6.73M | 41.27M | 342.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $17.03B | 44.80 | 76.24% | ― | 7.64% | 369.79% | |
77 Outperform | $12.74B | 31.99 | 12.96% | ― | 11.34% | ― | |
67 Neutral | ¥250.86B | 13.17 | 6.48% | 2.78% | 5.05% | -11.96% | |
64 Neutral | $5.60B | 37.98 | -39.97% | ― | 2.18% | -32.87% | |
62 Neutral | $893.95M | ― | -69.51% | ― | -10.55% | 9.27% | |
55 Neutral | $7.06B | ― | 17.86% | ― | -0.89% | 46.62% | |
52 Neutral | $867.65M | ― | -5.90% | ― | -2.37% | 95.07% |
On June 23, 2025, Chewy, Inc. entered into an Underwriting Agreement with Buddy Chester Sub LLC and J.P. Morgan Securities LLC for the sale of 23,952,096 shares of Class A common stock at $41.95 per share, with an additional option for 3,592,815 shares, which was exercised on June 24, 2025. The offering closed on June 25, 2025, with Chewy not selling any shares or receiving proceeds, while the company and seller agreed to indemnify the underwriters against certain liabilities. Additionally, on June 20, 2025, Chewy agreed to repurchase $100 million worth of shares from the Seller, closing on June 25, 2025, with the repurchased shares being cancelled and retired. This repurchase was approved by a special committee of independent directors and did not utilize the company’s existing share repurchase program.
The most recent analyst rating on (CHWY) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Chewy stock, see the CHWY Stock Forecast page.
On May 7, 2025, Chewy, Inc. announced the resignation of its Chief Financial Officer, David Reeder, who is leaving to become a CEO in the semiconductor industry. The company confirmed that his departure was not due to any disagreements and reaffirmed its first quarter fiscal 2025 guidance, indicating continued business momentum and strategic growth initiatives. Reeder will remain in his role until June to ensure a smooth transition, as Chewy searches for his successor.
The most recent analyst rating on (CHWY) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Chewy stock, see the CHWY Stock Forecast page.
On April 24, 2025, Chewy, Inc. expanded its board of directors from thirteen to fourteen members by appointing Dr. Nat Goldhaber as a Class I director, with his term set to expire at the company’s annual meeting of stockholders in 2026. Dr. Goldhaber, an independent director under SEC and NYSE rules, brings extensive experience in venture capital, clean energy, and healthcare investments, having co-founded Claremont Creek Ventures. His appointment is expected to enhance Chewy’s strategic direction, leveraging his expertise in technology and energy sectors.